Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS' 2012 Budget Looks To Biosimilars, Ban On Brand/Generic Deals To Offset Costs

This article was originally published in The Pink Sheet Daily

Executive Summary

The two legislative proposals contained in the budget seem unlikely to pass in the current Congress.

You may also be interested in...



PCMA Makes Specific Rx Cost-Cutting Proposals To Congressional "Super Committee"

Many of the proposals will put the PBM industry association at odds with pharmaceutical manufacturers and pharmacies as they try to influence the legislation that will be worked out by the Joint Select Committee on Deficit Reduction over the next three months.

PCMA Makes Specific Rx Cost-Cutting Proposals To Congressional "Super Committee"

Many of the proposals will put the PBM industry association at odds with pharmaceutical manufacturers and pharmacies as they try to influence the legislation that will be worked out by the Joint Select Committee on Deficit Reduction over the next three months.

Not Another FDAAA – Observers Expect Fewer FDA Reforms In PDUFA V

Congress is not expected to pile as many new responsibilities on FDA in the upcoming Prescription Drug User Fee Act reauthorization as in 2007’s FDA Amendments Act.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel